Home › Companies › ULTRAGENYX PHARMACEUTICAL INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed June 21, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2024: 6 items on ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed June 21, 2024: 2 approved · 4 passed (calculated).
Notable dissent: 2 directors (11.1%, 10.6% against); 1 say-on-pay vote (73.9% support); 1 other board item (30.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Nantahala Capital (13F, 2.3%, as of September 30, 2026)
Explore ULTRAGENYX PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are ULTRAGENYX PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 21, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Deborah Dunsire, M.D. | 66,396,499 | -- | -- | 7,865,348 | 4,273,815 | 89% | Passed (calculated) | — |
| Elect Director: Michael Narachi | 66,013,202 | -- | -- | 8,248,645 | 4,273,815 | 89% | Passed (calculated) | — |
| Elect Director: Corsee Sanders, Ph.D. | 68,077,817 | -- | -- | 6,184,030 | 4,273,815 | 92% | Passed (calculated) | — |
| Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were | 51,942,752 | 22,299,718 | 19,377 | -- | 4,273,815 | 70% | Approved | — |
| Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea | 77,155,452 | 1,362,194 | 18,016 | -- | -- | 98% | Approved | — |
| 4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described | 54,803,351 | 19,320,182 | 138,314 | -- | 4,273,815 | 74% | Passed (calculated) | — |
Source: ULTRAGENYX PHARMACEUTICAL INC., Form 8-K, filed with the SEC on June 21, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
326 asset managers disclosed a vote on at least one ULTRAGENYX PHARMACEUTICAL INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: Nominees: Corsee D. Sanders, Ph.D.
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Corsee Sanders, Ph.D.”): 68,077,817 for, 6,184,030 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 28,421,970 for, 3,572,979 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 2,612,411 | Withhold |
| Fidelity | 2,165,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,106 | 0 | 0 | 324 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 490,540 | 0 | 0 | 0 | For |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 416,360 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 331,321 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 215,422 | 0 | 0 | 49,165 | Mixed |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 89,043 | 0 | 0 | 133,658 | Mixed |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 0 | 206,002 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 204,203 | Withhold |
| Equitable | 159,247 | 0 | 0 | 16,828 | Mixed |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Nominees: Deborah Dunsire, M.D.
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Deborah Dunsire, M.D.”): 66,396,499 for, 7,865,348 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 26,956,199 for, 5,038,733 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 2,612,411 | Withhold |
| Fidelity | 2,144,092 | 0 | 0 | 21,749 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,106 | 0 | 0 | 324 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 8,958 | 0 | 0 | 481,582 | Withhold |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 416,360 | Withhold |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 331,321 | Withhold |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 215,422 | 0 | 0 | 49,165 | Mixed |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 7,674 | 0 | 0 | 215,027 | Withhold |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 0 | 206,002 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 204,203 | Withhold |
| Equitable | 25,857 | 0 | 0 | 150,218 | Mixed |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Nominees: Michael Narachi
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Michael Narachi”): 66,013,202 for, 8,248,645 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 26,954,329 for, 5,040,586 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 2,612,411 | Withhold |
| Fidelity | 2,144,092 | 0 | 0 | 21,749 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,106 | 0 | 0 | 324 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 8,958 | 0 | 0 | 481,582 | Withhold |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 416,360 | Withhold |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 331,321 | Withhold |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 215,422 | 0 | 0 | 49,165 | Mixed |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 7,674 | 0 | 0 | 215,027 | Withhold |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 0 | 206,002 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 204,203 | Withhold |
| Equitable | 25,857 | 0 | 0 | 150,218 | Mixed |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
70% Approved · of votes cast
Description as filed by funds: Approval of the Amended and Restated 2023 Incentive Plan.
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 51,942,752 for, 22,299,718 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,612,411 | 0 | 0 | 0 | For |
| Fidelity | 1,292,666 | 873,175 | 0 | 0 | Mixed |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,558 | 1,515,872 | 0 | 0 | Against |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 0 | 867,035 | 0 | 0 | Against |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 490,540 | 0 | 0 | Against |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 416,360 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 0 | 335,798 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 331,321 | 0 | 0 | Against |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 324,358 | 0 | 0 | Against |
| First Trust | 0 | 280,034 | 0 | 0 | Against |
| John Hancock | 49,165 | 215,422 | 0 | 0 | Mixed |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 0 | 256,385 | 0 | 0 | Against |
| Principal | 133,658 | 89,043 | 0 | 0 | Mixed |
| FINANCIAL INVESTORS TRUST | 206,002 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 204,203 | 0 | 0 | Against |
| Equitable | 42,685 | 133,390 | 0 | 0 | Mixed |
Fund voting reports, all 100 managers: 23,925,313 for, 7,917,068 against, 11,435 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 737,496 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 140,000 | 0 | 0 | 0 | For |
| Keel Point, LLC | 0 | 41 | 0 | 0 | Against |
Institutional-manager reports, all 3 managers: 877,496 for, 41 against.
Combines 9 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Prior year: 94.7% for (June 7, 2023 meeting) ▼ 20.7 pts
Description as filed by funds: Advisory (non-binding) vote to approve the compensation of our named executive officers.
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its ”): 54,803,351 for, 19,320,182 against, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,651,123 | 741,418 | 0 | 0 | Mixed |
| T. Rowe Price | 2,612,411 | 0 | 0 | 0 | For |
| Fidelity | 2,144,092 | 21,749 | 0 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,515,413 | 2,017 | 0 | 0 | For |
| Legg Mason | 0 | 1,333,988 | 0 | 0 | Against |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 8,958 | 481,582 | 0 | 0 | Against |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 416,360 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 0 | 335,798 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 331,321 | 0 | 0 | Against |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 324,358 | 0 | 0 | Against |
| First Trust | 0 | 280,034 | 0 | 0 | Against |
| John Hancock | 125,670 | 138,917 | 0 | 0 | Mixed |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 0 | 256,385 | 0 | 0 | Against |
| Principal | 133,658 | 89,043 | 0 | 0 | Mixed |
| FINANCIAL INVESTORS TRUST | 206,002 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 204,203 | 0 | 0 | Against |
| Equitable | 22,115 | 153,960 | 0 | 0 | Mixed |
Fund voting reports, all 101 managers: 25,450,499 for, 6,421,837 against, 11,435 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 6,742,286 | 0 | 0 | 0 | For |
| Wellington | 3,746,452 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,308,746 | 0 | 0 | 0 | For |
| SANDS CAPITAL MANAGEMENT, LLC | 2,755,249 | 0 | 0 | 0 | For |
| State Street | 2,557,095 | 37,242 | 0 | 0 | For |
| BlackRock | 2,420,140 | 19,967 | 0 | 0 | For |
| Clearbridge Investments, LLC | 0 | 2,303,927 | 0 | 0 | Against |
| Federated Hermes | 1,882,354 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,756,055 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 0 | 1,676,811 | 0 | 0 | Against |
| BAKER BROS. ADVISORS LP | 1,466,547 | 0 | 0 | 0 | For |
| Man Group plc | 0 | 1,454,680 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,340,869 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 1,212,260 | 0 | 0 | Against |
| Invesco | 952,169 | 0 | 0 | 0 | For |
| Fidelity | 750,552 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 737,496 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 0 | 693,685 | 0 | 0 | Against |
| Candriam S.C.A. | 0 | 606,897 | 0 | 0 | Against |
| Avidity Partners Management LP | 604,543 | 0 | 0 | 0 | For |
| Woodline Partners LP | 588,838 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 0 | 560,076 | 0 | 0 | Against |
| BNP Paribas Asset Management Holding S.A. | 0 | 507,513 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 0 | 501,296 | 0 | 0 | Against |
| Charles Schwab | 499,199 | 0 | 0 | 0 | For |
Institutional-manager reports, all 251 managers: 36,760,821 for, 15,117,314 against, 122,555 abstained, 186 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 98.6% for (June 7, 2023 meeting) ▼ 0.3 pts
Description as filed by funds: Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 77,155,452 for, 1,362,194 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of ULTRAGENYX PHARMACEUTICAL INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 29,938 for).
The 102 asset managers below reported 31,968,225 for, 14,128 against, 11,435 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,392,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,612,411 | 0 | 0 | 0 | For |
| Fidelity | 2,165,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,882,350 | 0 | 0 | 0 | For |
| BlackRock | 1,744,575 | 0 | 0 | 0 | For |
| Hartford | 1,581,556 | 0 | 0 | 0 | For |
| State Street | 1,517,195 | 235 | 0 | 0 | For |
| Legg Mason | 1,333,988 | 0 | 0 | 0 | For |
| Invesco | 867,035 | 0 | 0 | 0 | For |
| TOUCHSTONE FUNDS GROUP TRUST | 776,877 | 0 | 0 | 0 | For |
| BNY Mellon | 490,540 | 0 | 0 | 0 | For |
| Charles Schwab | 488,143 | 0 | 0 | 0 | For |
| AllianceBernstein | 416,360 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 359,000 | 0 | 0 | 0 | For |
| TIAA | 335,798 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 331,321 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 324,358 | 0 | 0 | 0 | For |
| First Trust | 280,034 | 0 | 0 | 0 | For |
| John Hancock | 264,587 | 0 | 0 | 0 | For |
| Northwestern Mutual | 259,150 | 0 | 0 | 0 | For |
| MFS | 256,385 | 0 | 0 | 0 | For |
| Principal | 222,701 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 206,002 | 0 | 0 | 0 | For |
| Goldman Sachs | 204,203 | 0 | 0 | 0 | For |
| Equitable | 176,075 | 0 | 0 | 0 | For |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 83,094,037 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.51% |
| 2 | T. Rowe Price | 3.14% |
| 3 | Fidelity | 2.61% |
| 4 | Federated Hermes | 2.27% |
| 5 | BlackRock | 2.10% |
| 6 | Hartford | 1.90% |
| 7 | State Street | 1.83% |
| 8 | Legg Mason | 1.61% |
| 9 | Invesco | 1.04% |
| 10 | TOUCHSTONE FUNDS GROUP TRUST | 0.93% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 8.11% |
| 2 | Wellington | 4.51% |
| 3 | T. Rowe Price | 3.98% |
| 4 | SANDS CAPITAL MANAGEMENT, LLC | 3.32% |
| 5 | State Street | 3.12% |
| 6 | BlackRock | 2.94% |
| 7 | Clearbridge Investments, LLC | 2.77% |
| 8 | Federated Hermes | 2.27% |
| 9 | Rock Springs Capital Management LP | 2.11% |
| 10 | SUVRETTA CAPITAL MANAGEMENT, LLC | 2.02% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 10,132,728 | 12.19% | Form 13F, quarter ended March 31, 2024 |
| FMR (Fidelity) | 7,283,296 | 8.77% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 6,425,263 | 7.73% | Form 13F, quarter ended March 31, 2024 |
| Wellington Management | 4,097,975 | 4.93% | Form 13F, quarter ended March 31, 2024 |
| JPMorgan Chase | 4,011,429 | 4.83% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 3,568,873 | 4.29% | Form 13F, quarter ended March 31, 2024 |
| State Street | 2,851,250 | 3.43% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 1,339,826 | 1.61% | Form 13F, quarter ended March 31, 2024 |
| BNY Mellon | 911,656 | 1.10% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 910,183 | 1.10% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 83,094,037 shares outstanding, as reported by ULTRAGENYX PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ULTRAGENYX PHARMACEUTICAL INC.'s shareholder meeting held June 18, 2024, in the 2023-2024 proxy season, 326 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 2,242 separate fund positions. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ULTRAGENYX PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 21, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ULTRAGENYX PHARMACEUTICAL INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ULTRAGENYX PHARMACEUTICAL INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ULTRAGENYX PHARMACEUTICAL (RARE) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ultragenyx-pharmaceutical-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.